Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(66.7%)
Phase 3
1(33.3%)
3Total
Phase 4(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01707979Completed

NIR- and Multifrequent Impedance Spectroscopy on the Skin in Type 1 Diabetes

Role: lead

NCT00346996Phase 4Completed

Insulin Analogues and Severe Hypoglycaemia

Role: lead

NCT00607737Phase 4Completed

Applications Site Reactions After Injection of Insulin Detemir and Saline in Subjects With Diabetes

Role: lead

NCT00699426Phase 3Completed

The Effect of Nexium and Probiotics on Insulin Secretion and Cardiovascular Risk Factors in Patients With Type 2 Diabetes

Role: lead

All 4 trials loaded